Recent interest in myoblast transfer and in the use of myoblasts as ve
hicles in gene therapy has made it important to understand the potenti
al immunogenicity of allogeneic or neoantigen-expressing myoblasts. Gi
ven the problems of producing a pure population of myoblasts, in this
study we used a tumour-derived muscle cell line (TE671), with phenotyp
ic features of myoblasts, which we transfected to express HLA-DR1. How
ever, this cell line was unable to stimulate either established HLA-DR
1-specific alloreactive T cell clones or a primary alloresponse. Nor c
ould it present haemagglutinin peptide HA 306-324 to DR1-restricted, H
A 306-324-specific T cell clones or lines. Indeed, preincubation with
DR1-expressing TE671 and HA 306-324 rendered such T cells tolerant as
judged by their subsequent inability to proliferate in response to a D
R1+ B cell line plus peptide HA 306-324. These results imply that myob
lasts do not provide costimulatory signals, and are therefore unlikely
to stimulate allospecific T cells following myoblasts transplantation
or to initiate neoantigen-specific immune responses following in vivo
transfection.